Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

TUFT1 interacts with RABGAP1 and regulates mTORC1 signaling.

Kawasaki N, Isogaya K, Dan S, Yamori T, Takano H, Yao R, Morishita Y, Taguchi L, Morikawa M, Heldin CH, Noda T, Ehata S, Miyazono K, Koinuma D.

Cell Discov. 2018 Jan 9;4:1. doi: 10.1038/s41421-017-0001-2. eCollection 2018.

2.

Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors.

Ohashi Y, Okamura M, Katayama R, Fang S, Tsutsui S, Akatsuka A, Shan M, Choi HW, Fujita N, Yoshimatsu K, Shiina I, Yamori T, Dan S.

Oncotarget. 2017 Dec 6;9(2):1641-1655. doi: 10.18632/oncotarget.22895. eCollection 2018 Jan 5.

3.

Family-wide Analysis of the Inhibition of Arf Guanine Nucleotide Exchange Factors with Small Molecules: Evidence of Unique Inhibitory Profiles.

Benabdi S, Peurois F, Nawrotek A, Chikireddy J, Cañeque T, Yamori T, Shiina I, Ohashi Y, Dan S, Rodriguez R, Cherfils J, Zeghouf M.

Biochemistry. 2017 Sep 26;56(38):5125-5133. doi: 10.1021/acs.biochem.7b00706. Epub 2017 Sep 13.

PMID:
28858527
4.

Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole.

Nakamura T, Okabe S, Yoshida H, Iida K, Ma Y, Sasaki S, Yamori T, Shin-Ya K, Nakano I, Nagasawa K, Seimiya H.

Sci Rep. 2017 Jun 15;7(1):3605. doi: 10.1038/s41598-017-03785-8.

5.

A novel thiophene-3-carboxamide analog of annonaceous acetogenin exhibits antitumor activity via inhibition of mitochondrial complex I.

Akatsuka A, Kojima N, Okamura M, Dan S, Yamori T.

Pharmacol Res Perspect. 2016 Jul 12;4(4):e00246. doi: 10.1002/prp2.246. eCollection 2016 Aug.

6.

Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors.

Narita K, Matsuhara K, Itoh J, Akiyama Y, Dan S, Yamori T, Ito A, Yoshida M, Katoh T.

Eur J Med Chem. 2016 Oct 4;121:592-609. doi: 10.1016/j.ejmech.2016.05.031. Epub 2016 May 18.

PMID:
27318982
7.

M-COPA, a novel Golgi system disruptor, suppresses apoptosis induced by Shiga toxin.

Hattori T, Watanabe-Takahashi M, Shiina I, Ohashi Y, Dan S, Nishikawa K, Yamori T, Naito M.

Genes Cells. 2016 Aug;21(8):901-6. doi: 10.1111/gtc.12386. Epub 2016 Jun 15.

8.

M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers.

Ohashi Y, Okamura M, Hirosawa A, Tamaki N, Akatsuka A, Wu KM, Choi HW, Yoshimatsu K, Shiina I, Yamori T, Dan S.

Cancer Res. 2016 Jul 1;76(13):3895-903. doi: 10.1158/0008-5472.CAN-15-2220. Epub 2016 Apr 12.

9.

Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.

Takemoto Y, Ito A, Niwa H, Okamura M, Fujiwara T, Hirano T, Handa N, Umehara T, Sonoda T, Ogawa K, Tariq M, Nishino N, Dan S, Kagechika H, Yamori T, Yokoyama S, Yoshida M.

J Med Chem. 2016 Apr 28;59(8):3650-60. doi: 10.1021/acs.jmedchem.5b01732. Epub 2016 Apr 18.

PMID:
27088648
10.

Pyrrocidine A, a metabolite of endophytic fungi, has a potent apoptosis-inducing activity against HL60 cells through caspase activation via the Michael addition.

Uesugi S, Fujisawa N, Yoshida J, Watanabe M, Dan S, Yamori T, Shiono Y, Kimura K.

J Antibiot (Tokyo). 2016 Mar;69(3):133-40. doi: 10.1038/ja.2015.103. Epub 2015 Oct 28.

PMID:
26506860
11.

Identification of a molecular target of kurahyne, an apoptosis-inducing lipopeptide from marine cyanobacterial assemblages.

Iwasaki A, Ohno O, Katsuyama S, Morita M, Sasazawa Y, Dan S, Simizu S, Yamori T, Suenaga K.

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5295-8. doi: 10.1016/j.bmcl.2015.09.044. Epub 2015 Sep 21.

PMID:
26428873
12.

Ridaifen G, tamoxifen analog, is a potent anticancer drug working through a combinatorial association with multiple cellular factors.

Ikeda K, Kamisuki S, Uetake S, Mizusawa A, Ota N, Sasaki T, Tsukuda S, Kusayanagi T, Takakusagi Y, Morohashi K, Yamori T, Dan S, Shiina I, Sugawara F.

Bioorg Med Chem. 2015 Sep 15;23(18):6118-24. doi: 10.1016/j.bmc.2015.08.001. Epub 2015 Aug 5.

PMID:
26314924
13.

Biselyngbyasides, cytotoxic marine macrolides, are novel and potent inhibitors of the Ca(2+) pumps with a unique mode of binding.

Morita M, Ogawa H, Ohno O, Yamori T, Suenaga K, Toyoshima C.

FEBS Lett. 2015 Jun 4;589(13):1406-11. doi: 10.1016/j.febslet.2015.04.056. Epub 2015 May 6.

14.

Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation.

Mashima T, Ushijima M, Matsuura M, Tsukahara S, Kunimasa K, Furuno A, Saito S, Kitamura M, Soma-Nagae T, Seimiya H, Dan S, Yamori T, Tomida A.

Cancer Sci. 2015 Jul;106(7):909-20. doi: 10.1111/cas.12682. Epub 2015 May 25.

15.

Stromal cells positively and negatively modulate the growth of cancer cells: stimulation via the PGE2-TNFα-IL-6 pathway and inhibition via secreted GAPDH-E-cadherin interaction.

Kawada M, Inoue H, Ohba S, Yoshida J, Masuda T, Yamasaki M, Usami I, Sakamoto S, Abe H, Watanabe T, Yamori T, Shibasaki M, Nomoto A.

PLoS One. 2015 Mar 18;10(3):e0119415. doi: 10.1371/journal.pone.0119415. eCollection 2015.

16.

Abdominal Infection Suppresses the Number and Activity of Intrahepatic Natural Killer Cells and Promotes Tumor Growth in a Murine Liver Metastasis Model.

Matsumoto Y, Tsujimoto H, Ono S, Shinomiya N, Miyazaki H, Hiraki S, Takahata R, Yoshida K, Saitoh D, Yamori T, Yamamoto J, Hase K.

Ann Surg Oncol. 2016 Feb;23 Suppl 2:S257-65. doi: 10.1245/s10434-015-4466-7. Epub 2015 Mar 10.

PMID:
25752891
17.

Synthesis of dansyl-labeled probe of thiophene analogue of annonaceous acetogenins for visualization of cell distribution and growth inhibitory activity toward human cancer cell lines.

Kojima N, Suga Y, Matsumoto T, Tanaka T, Akatsuka A, Yamori T, Dan S, Iwasaki H, Yamashita M.

Bioorg Med Chem. 2015 Mar 15;23(6):1276-83. doi: 10.1016/j.bmc.2015.01.037. Epub 2015 Jan 29.

PMID:
25684427
18.

Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474.

Isoyama S, Kajiwara G, Tamaki N, Okamura M, Yoshimi H, Nakamura N, Kawamura K, Nishimura Y, Namatame N, Yamori T, Dan S.

Cancer Sci. 2015 Feb;106(2):171-8. doi: 10.1111/cas.12582. Epub 2015 Jan 16.

19.

Extensive analysis of signaling pathway molecules in breast cancer: association with clinicopathological characteristics.

Horii R, Matsuura M, Dan S, Ushijima M, Uehiro N, Ogiya A, Honma N, Ito Y, Iwase T, Yamori T, Akiyama F.

Int J Clin Oncol. 2015 Jun;20(3):490-8. doi: 10.1007/s10147-014-0753-8. Epub 2014 Oct 15.

PMID:
25312293
20.

Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.

Momose I, Abe H, Watanabe T, Ohba S, Yamazaki K, Dan S, Yamori T, Masuda T, Nomoto A.

Cancer Sci. 2014 Dec;105(12):1609-15. doi: 10.1111/cas.12542. Epub 2014 Oct 21.

21.

Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.

Alewine C, Xiang L, Yamori T, Niederfellner G, Bosslet K, Pastan I.

Mol Cancer Ther. 2014 Nov;13(11):2653-61. doi: 10.1158/1535-7163.MCT-14-0132. Epub 2014 Sep 19.

22.

Thiophene-3-carboxamide analogue of annonaceous acetogenins as antitumor drug lead.

Kojima N, Fushimi T, Tatsukawa T, Tanaka T, Okamura M, Akatsuka A, Yamori T, Dan S, Iwasaki H, Yamashita M.

Eur J Med Chem. 2014 Oct 30;86:684-9. doi: 10.1016/j.ejmech.2014.09.026. Epub 2014 Sep 9.

PMID:
25226228
23.

In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.

Kong D, Yamori T, Yamazaki K, Dan S.

Invest New Drugs. 2014 Dec;32(6):1134-43. doi: 10.1007/s10637-014-0152-z. Epub 2014 Aug 26.

PMID:
25152245
24.

In vitro antitumor activity of stellettin B, a triterpene from marine sponge Jaspis stellifera, on human glioblastoma cancer SF295 cells.

Tang SA, Zhou Q, Guo WZ, Qiu Y, Wang R, Jin M, Zhang W, Li K, Yamori T, Dan S, Kong D.

Mar Drugs. 2014 Jul 15;12(7):4200-13. doi: 10.3390/md12074200.

25.

Total synthesis of burkholdacs A and B and 5,6,20-tri-epi-burkholdac A: HDAC inhibition and antiproliferative activity.

Fukui Y, Narita K, Dan S, Yamori T, Ito A, Yoshida M, Katoh T.

Eur J Med Chem. 2014 Apr 9;76:301-13. doi: 10.1016/j.ejmech.2014.02.044. Epub 2014 Feb 18.

PMID:
24589486
26.

[The 15th result of screening for antineoplastic agents].

Yamori T, Uehara Y, Fukazawa H, Yoshida M, Imoto M, Kiyomiya H, Mashima T, Manakami T, Kawata M, Nagata H, Dan S, Matsuura M, Kakeya H, Tomita A.

Gan To Kagaku Ryoho. 2013 Apr;40 Suppl 1:116-47. No abstract available.

PMID:
24171229
27.

[The 14th result of screening for antineoplastic agents].

Yamori T, Uehara Y, Fukazawa H, Yoshida M, Imoto M, Kiyomiya H, Minakami T, Kawata M, Nagata H, Matsuura M.

Gan To Kagaku Ryoho. 2013 Apr;40 Suppl 1:18-114. No abstract available.

PMID:
24171228
28.

A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells.

Yao R, Kondoh Y, Natsume Y, Yamanaka H, Inoue M, Toki H, Takagi R, Shimizu T, Yamori T, Osada H, Noda T.

Oncogene. 2014 Aug 14;33(33):4242-52. doi: 10.1038/onc.2013.382. Epub 2013 Sep 30.

PMID:
24077290
29.

Design, synthesis, and in vitro cancer cell growth inhibition evaluation and antimalarial testing of trioxanes installed in cyclic 2-enoate substructures.

Hossain MI, Świtalska M, Peng W, Takashima M, Wang N, Kaiser M, Wietrzyk J, Dan S, Yamori T, Inokuchi T.

Eur J Med Chem. 2013 Nov;69:294-309. doi: 10.1016/j.ejmech.2013.08.008. Epub 2013 Aug 13.

PMID:
24056020
30.

Ridaifen-SB8, a novel tamoxifen derivative, induces apoptosis via reactive oxygen species-dependent signaling pathway.

Guo WZ, Shiina I, Wang Y, Umeda E, Watanabe C, Uetake S, Ohashi Y, Yamori T, Dan S.

Biochem Pharmacol. 2013 Nov 1;86(9):1272-84. doi: 10.1016/j.bcp.2013.08.020. Epub 2013 Aug 22.

PMID:
23973528
31.

Novel tamoxifen derivative Ridaifen-B induces Bcl-2 independent autophagy without estrogen receptor involvement.

Nagahara Y, Takeyoshi M, Sakemoto S, Shiina I, Nakata K, Fujimori K, Wang Y, Umeda E, Watanabe C, Uetake S, Yamori T, Dan S, Yoshimi Y, Shinomiya T, Ikekita M.

Biochem Biophys Res Commun. 2013 Jun 14;435(4):657-63. doi: 10.1016/j.bbrc.2013.05.040. Epub 2013 May 18.

PMID:
23688426
32.

Synthesis of antitumor azolato-bridged dinuclear platinum(ii) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles.

Komeda S, Takayama H, Suzuki T, Odani A, Yamori T, Chikuma M.

Metallomics. 2013 May;5(5):461-8. doi: 10.1039/c3mt00040k. Epub 2013 Apr 23.

PMID:
23608770
33.

Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, Song Y, Engelman JA, Fujita N.

Cancer Res. 2013 May 15;73(10):3087-96. doi: 10.1158/0008-5472.CAN-12-3256. Epub 2013 Apr 18.

34.

Structure-activity relationships of hybrid annonaceous acetogenins: powerful growth inhibitory effects of their connecting groups between heterocycle and hydrophobic carbon chain bearing THF ring on human cancer cell lines.

Kojima N, Fushimi T, Tatsukawa T, Yoshimitsu T, Tanaka T, Yamori T, Dan S, Iwasaki H, Yamashita M.

Eur J Med Chem. 2013 May;63:833-9. doi: 10.1016/j.ejmech.2013.03.009. Epub 2013 Mar 14.

PMID:
23587837
35.

Search for novel anti-tumor agents from ridaifens using JFCR39, a panel of human cancer cell lines.

Guo WZ, Wang Y, Umeda E, Shiina I, Dan S, Yamori T.

Biol Pharm Bull. 2013;36(6):1008-16. Epub 2013 Apr 9.

36.

Total synthesis of bicyclic depsipeptides spiruchostatins C and D and investigation of their histone deacetylase inhibitory and antiproliferative activities.

Narita K, Fukui Y, Sano Y, Yamori T, Ito A, Yoshida M, Katoh T.

Eur J Med Chem. 2013 Feb;60:295-304. doi: 10.1016/j.ejmech.2012.12.023. Epub 2012 Dec 21.

PMID:
23313638
37.

Total synthesis of AMF-26, an antitumor agent for inhibition of the Golgi system, targeting ADP-ribosylation factor 1.

Shiina I, Umezaki Y, Ohashi Y, Yamazaki Y, Dan S, Yamori T.

J Med Chem. 2013 Jan 10;56(1):150-9. doi: 10.1021/jm301695c. Epub 2012 Dec 28.

PMID:
23214926
38.

Identification of transporters associated with Etoposide sensitivity of stomach cancer cell lines and methotrexate sensitivity of breast cancer cell lines by quantitative targeted absolute proteomics.

Obuchi W, Ohtsuki S, Uchida Y, Ohmine K, Yamori T, Terasaki T.

Mol Pharmacol. 2013 Feb;83(2):490-500. doi: 10.1124/mol.112.081083. Epub 2012 Nov 29.

39.

Development of a gene expression database and related analysis programs for evaluation of anticancer compounds.

Ushijima M, Mashima T, Tomida A, Dan S, Saito S, Furuno A, Tsukahara S, Seimiya H, Yamori T, Matsuura M.

Cancer Sci. 2013 Mar;104(3):360-8. doi: 10.1111/cas.12071. Epub 2013 Jan 4.

41.

Establishment of phosphatidylinositol 3-kinase inhibitor-resistant cancer cell lines and therapeutic strategies for overcoming the resistance.

Isoyama S, Dan S, Nishimura Y, Nakamura N, Kajiwara G, Seki M, Irimura T, Yamori T.

Cancer Sci. 2012 Nov;103(11):1955-60. doi: 10.1111/cas.12004. Epub 2012 Oct 22.

42.

Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.

Kimura K, Sakamoto Y, Fujisawa N, Uesugi S, Aburai N, Kawada M, Ohba S, Yamori T, Tsuchiya E, Koshino H.

Bioorg Med Chem. 2012 Jun 15;20(12):3887-97. doi: 10.1016/j.bmc.2012.04.025. Epub 2012 Apr 17.

PMID:
22575162
43.

Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats.

Haruta K, Mori S, Tamura N, Sasaki A, Nagamine M, Yaguchi S, Kamachi F, Enami J, Kobayashi S, Yamori T, Takasaki Y.

Inflamm Res. 2012 Jun;61(6):551-62. doi: 10.1007/s00011-012-0444-8. Epub 2012 Feb 15.

PMID:
22349137
44.

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Kong D, Yamori T.

Bioorg Med Chem. 2012 Mar 15;20(6):1947-51. doi: 10.1016/j.bmc.2012.01.017. Epub 2012 Jan 21. Review.

45.

Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb.

Miyazaki T, Pan Y, Joshi K, Purohit D, Hu B, Demir H, Mazumder S, Okabe S, Yamori T, Viapiano M, Shin-ya K, Seimiya H, Nakano I.

Clin Cancer Res. 2012 Mar 1;18(5):1268-80. doi: 10.1158/1078-0432.CCR-11-1795. Epub 2012 Jan 9.

46.

Potentiation of bleomycin in Jurkat cells by fungal pycnidione.

Kaneko M, Matsuda D, Ohtawa M, Fukuda T, Nagamitsu T, Yamori T, Tomoda H.

Biol Pharm Bull. 2012;35(1):18-28.

47.

AMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy.

Ohashi Y, Iijima H, Yamaotsu N, Yamazaki K, Sato S, Okamura M, Sugimoto K, Dan S, Hirono S, Yamori T.

J Biol Chem. 2012 Feb 3;287(6):3885-97. doi: 10.1074/jbc.M111.316125. Epub 2011 Dec 9.

48.

ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo.

Dan S, Okamura M, Mukai Y, Yoshimi H, Inoue Y, Hanyu A, Sakaue-Sawano A, Imamura T, Miyawaki A, Yamori T.

Eur J Cancer. 2012 Apr;48(6):936-43. doi: 10.1016/j.ejca.2011.10.006. Epub 2011 Nov 14.

PMID:
22088482
49.

Design and synthesis of C35-fluorinated solamins and their growth inhibitory activities against human cancer cell lines.

Kojima N, Suga Y, Hayashi H, Yamori T, Yoshimitsu T, Tanaka T.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5745-9. doi: 10.1016/j.bmcl.2011.08.011. Epub 2011 Aug 10.

PMID:
21875800
50.

Inhibitory activity of flavonoids against class I phosphatidylinositol 3-kinase isoforms.

Kong D, Zhang Y, Yamori T, Duan H, Jin M.

Molecules. 2011 Jun 21;16(6):5159-67. doi: 10.3390/molecules16065159.

Supplemental Content

Loading ...
Support Center